Skip to Content

CONTACT-2: Cabozantinib + Atezolizumab for Patients with Metastatic Castration-Resistant Prostate Cancer

Dr. Neeraj Agarwal, professor of medicine and director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, presented the primary results of the phase III CONTACT-2 study at the ASCO GU meeting in 2024. Listen as Dr. Neeraj Agarwal explains why he is hoping to make the drug combination cabozantinib + atezolizumab available at his clinic.

Neeraj Agarwal

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top